Last updated on December 2017

A phase II randomised, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of 4 oral doses of BI 425809 once daily over 12 week treatment period in patients with Schizophrenia

Brief description of study

Clinical trial of BI 425809 effect on cognition and functional capacity in schizophrenia.

Clinical Study Identifier: TX155170

Find a site near you

Start Over

Northwest Clinical Research Center

1951 152nd Pl NE Suite 200 Bellevue, WA USA
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.